1,658 Shares in Danaher Corporation $DHR Purchased by Turtle Creek Wealth Advisors LLC

Key Points

• Turtle Creek Wealth Advisors LLC acquired 1,658 shares of Danaher Corporation, valued at approximately $328,000, during the second quarter.
• Danaher recently reported $1.80 earnings per share for the last quarter, beating analyst expectations, and set its FY 2025 guidance at 7.700-7.800 EPS.
• The company announced a quarterly dividend of $0.32, representing a 0.6% yield, to be paid on October 31st.

Turtle Creek Wealth Advisors LLC acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,658 shares of the conglomerate's stock, valued at approximately $328,000.

Several other institutional investors have also bought and sold shares of DHR. Nuveen LLC acquired a new stake in Danaher in the first quarter worth about $833,941,000. Invesco Ltd. boosted its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock valued at $651,515,000 after purchasing an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock valued at $784,745,000 after purchasing an additional 722,636 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DHR. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Weiss Ratings restated a "hold (c-)" rating on shares of Danaher in a research report on Wednesday, October 8th. Rothschild & Co Redburn restated a "neutral" rating and set a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Guggenheim restated a "buy" rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $244.60.

Danaher Stock Performance

Shares of Danaher stock opened at $210.86 on Friday. The stock has a market cap of $150.99 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.77. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $201.43 and a 200-day simple moving average of $197.23.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.